← Back to patent-cliff list
YMI-024
Tier C — Watch / tradeYMI-024
Novartis Ag
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Coronary artery lesion, Coronary artery disease, Inflammatory disease
Regional status
US
-
EU
-
China
Phase I
2026-09-22
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of YMI-024?
Approved indications include: Coronary artery lesion, Coronary artery disease, Inflammatory disease.
When does the YMI-024 patent expire?
No public expiry year is available for YMI-024 yet; this page updates once verified.
How do I get a quote for YMI-024 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28